SGO 2019: Maintenance Rucaparib Effective for All Age Groups in Ovarian Cancer, but Safety Questioned

Leggi l'articolo originale


The results of a post-hoc exploratory analysis of the phase III ARIEL3 trial were promising, but with some caveats.

Lascia un commento